A fresh surge of COVID-19 infections is being reported across parts of Asia, especially in countries like Singapore, Hong Kong, China, and Thailand, largely due to the spread of the JN.1 Omicron subvariant. While the rise in cases has raised concerns, health experts emphasize that current vaccines, especially updated boosters, still offer protection. In India, the situation remains stable with minimal increase in cases, though health authorities continue to monitor the situation closely.
Rising Cases and Variant Spread
Singapore has witnessed a sharp increase in daily COVID-19 cases, crossing 14,000 in early May 2025, up from around 11,100 cases in late April. Though hospitalizations have increased, the number of ICU admissions has slightly declined, indicating that while more people are getting infected, the severity may not be worsening. The new infections are mainly caused by Omicron subvariants JN.1 and its offshoots LF.7 and NB.1.8, which together account for over two-thirds of the sequenced samples in the region. Health experts attribute this surge partly to waning immunity over time and anticipate these periodic waves.
Despite these developments in Asia, India has reported only 93 active COVID-19 cases as of mid-May 2025. Mumbai doctors have noted a small rise in mild infections among younger people but do not see evidence of a new wave at this point. Health officials advise continued caution, especially due to increased transmission in neighboring countries.
Understanding the JN.1 Variant and Vaccine Effectiveness
JN.1 is a descendant of the Omicron BA.2.86 lineage identified in August 2023. It was designated a Variant of Interest by the WHO due to its roughly 30 mutations aimed at evading immune responses. Although BA.2.86 did not dominate globally, JN.1 evolved with additional mutations that improve its transmissibility while retaining its immune escape capabilities.
Studies show that the JN.1 variant poses a greater challenge to the immune system, with antibodies from vaccinated or previously infected individuals being less effective at neutralizing it. However, the XBB.1.5 monovalent booster, designed to target the XBB.1.5 Omicron subvariant, has demonstrated moderate effectiveness (19% to 49%) in preventing symptomatic JN.1 infections. This booster is available globally through vaccines like Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax, with India offering the Covovax XBB.1.5 booster.
Symptoms of JN.1 resemble those of other COVID-19 variants, including sore throat, fever, cough, fatigue, and loss of taste or smell. Most cases are mild and manageable at home, with severity more dependent on individual health than the variant itself. Due to widespread vaccination and previous infections, JN.1 is less likely to cause severe illness compared to earlier strains.
